Answers are grounded in this paper and cite their sources.
Having SARS-CoV-2 anti-nucleocapsid antibodies provides almost 80% protection against SARS-CoV-2 re-infection for a period of at least 8 months.
No takes yet. Share an insight, caveat, or question.
Köhler et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: